Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Massmutual Trust Co. FSB ADV

Massmutual Trust Co. FSB ADV lifted its position in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 25.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 274 shares of the medical instruments supplier’s stock after purchasing an additional 56 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Becton, Dickinson and were worth $68,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in BDX. Icapital Wealth LLC acquired a new position in shares of Becton, Dickinson and in the 1st quarter valued at $31,000. Disciplined Investments LLC acquired a new position in shares of Becton, Dickinson and in the 1st quarter valued at $32,000. Rosenberg Matthew Hamilton raised its position in Becton, Dickinson and by 61.5% during the first quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock worth $34,000 after acquiring an additional 48 shares during the period. Core Alternative Capital raised its position in Becton, Dickinson and by 688.2% during the first quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 117 shares during the period. Finally, EverSource Wealth Advisors LLC acquired a new position in Becton, Dickinson and during the fourth quarter worth $38,000. 86.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and

In other news, EVP Samrat S. Khichi sold 9,185 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the transaction, the executive vice president now directly owns 5,928 shares in the company, valued at $1,543,888.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.13, for a total value of $2,518,735.00. Following the transaction, the chief executive officer now directly owns 28,878 shares in the company, valued at approximately $7,656,424.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Samrat S. Khichi sold 9,185 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the completion of the transaction, the executive vice president now owns 5,928 shares in the company, valued at $1,543,888.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 19,160 shares of company stock worth $5,036,751. Insiders own 0.50% of the company’s stock.

Becton, Dickinson and Stock Performance

Shares of Becton, Dickinson and stock opened at $251.26 on Tuesday. The firm has a market capitalization of $71.66 billion, a P/E ratio of 43.32, a P/E/G ratio of 3.33 and a beta of 0.57. Becton, Dickinson and Company has a 52 week low of $231.46 and a 52 week high of $280.62. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.58. The firm’s 50 day moving average is $251.96 and its two-hundred day moving average is $254.56.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $4.64 billion for the quarter, compared to analyst estimates of $4.47 billion. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The firm’s revenue was down 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.74 earnings per share. Research analysts forecast that Becton, Dickinson and Company will post 11.31 EPS for the current fiscal year.

Becton, Dickinson and Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be given a dividend of $0.87 per share. The ex-dividend date is Thursday, September 8th. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.39%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 60.00%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BDX. The Goldman Sachs Group upped their price objective on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Saturday, September 10th. Morgan Stanley dropped their target price on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a report on Friday, July 15th. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. Finally, Wells Fargo & Company raised shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price for the company in a report on Friday, June 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $277.63.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.